gms | German Medical Science

130. Kongress der Deutschen Gesellschaft für Chirurgie

Deutsche Gesellschaft für Chirurgie

30.04. - 03.05.2013, München

Circulating tumor cells in neuroendocrine neoplasms

Meeting Abstract

  • Andreas Raffel - Uniklink Düsseldorf, Klinik für Allgemein-, Viszeral- und Kinderchirurgie, Düsseldorf
  • Ellen Honisch - Uniklinik Düsseldorf, Klinik für Gynäkologie, Düsseldorf
  • Markus Krausch - Uniklink Düsseldorf, Klinik für Allgemein-, Viszeral- und Kinderchirurgie, Düsseldorf
  • Dieter Niederacher - Uniklinik Düsseldorf, Klinik für Gynäkologie, Düsseldorf
  • Martin Anlauf - Uniklinik Düsseldorf, Institut für Pathologie, Düsseldorf
  • Wolfgang Janni - Uniklinik Düsseldorf, Klinik für Gynäkologie, Düsseldorf
  • Wolfram Trudo Knoefel - Uniklink Düsseldorf, Klinik für Allgemein-, Viszeral- und Kinderchirurgie, Düsseldorf
  • Nick H Stoecklein - Uniklink Düsseldorf, Klinik für Allgemein-, Viszeral- und Kinderchirurgie, Düsseldorf

Deutsche Gesellschaft für Chirurgie. 130. Kongress der Deutschen Gesellschaft für Chirurgie. München, 30.04.-03.05.2013. Düsseldorf: German Medical Science GMS Publishing House; 2013. Doc13dgch017

doi: 10.3205/13dgch017, urn:nbn:de:0183-13dgch0178

Published: April 26, 2013

© 2013 Raffel et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Introduction: We (and others) have previously shown that neuroendocrine neoplasias (NEN) express EpCAM with increasing malignancy. Concluding on this we performed a prospective analyzed study for examing circulating tumor cells in blood of patients with NEN.

Material and methods: 29 patients with NEN (pancreas n=8; ileum n=12; pancreatic glucagonomatose n=2; colon n=2; n=1 (uterus, appendix, paracoxygeal, gastric, prostate) were evaluated prospectively by blood samples drawn for CTC isolation. Patients were classified according the TNM-classification. 7.5ml peripheral blood was analysed using the CellSearch® System for the presence of CTCs. We correlated the CTC count with progressive/non-progressive disease, presence/absence of metastases, MiB-1 and Chromogranin A level.

Results: In 55% of the investigated patients (n=16) we detected CTCs with a range of 1-35. There was a strong correlation between CTC detection and progressive disease (metastases) (94%/n=15). Only a moderate correlation was seen between CTC levels and metastatic burden and between CTC`s and Chromogranin A level. In cases with stable disease (n=13) (no metastases; low Chromogranin A level etc.) CTCs were not detected.

Conclusion: CTCs seem to be associated with progressive disease in NEN and may provide useful prognostic information given the variable survival rates in these tumors.